Biotest Aktiengesellschaft Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, sales was EUR 253.1 million compared to EUR 257.8 million a year ago. Net loss was EUR 19.9 million compared to EUR 18.2 million a year ago. Basic loss per share from continuing operations was EUR 0.5 compared to EUR 0.47 a year ago.